Edition:
United Kingdom

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

82.18EUR
9:09am GMT
Change (% chg)

€-0.16 (-0.19%)
Prev Close
€82.34
Open
€82.02
Day's High
€82.38
Day's Low
€81.58
Volume
58,744
Avg. Vol
561,715
52-wk High
€115.20
52-wk Low
€80.92

Select another date:

Wed, Feb 21 2018

BRIEF-Merck KGaA Invests Additional $47 Mln To Enhance Manufacturing And Distribution In Asia

* MERCK KGAA, DARMSTADT, GERMANY INVESTS ADDITIONAL $47 MILLION TO ENHANCE MANUFACTURING AND DISTRIBUTION IN ASIA

Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial

FRANKFURT Merck KGaA and Pfizer received a setback on Thursday for their drug Bavencio, which is a late starter in the rapidly evolving field of cancer immunotherapies.

UPDATE 1-Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial

* Merck still sees potential against lung cancer for Bavencio (Adds trial details, background on immunotherapies)

Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial

FRANKFURT, Feb 15 Merck KGaA and Pfizer's cancer drug Bavencio could not be shown to improve survival in lung cancer patients that had previously undergone unsuccessful chemotherapy, Merck said.

Exclusive - Merck's consumer health sale at risk as Nestle bows out: sources

LONDON/FRANKFURT The sale of Merck KGaA's consumer health unit has been thrown off track after Nestle has pulled out, leaving the race to buy the maker of Seven Seas vitamins without its main contender, sources familiar with the matter told Reuters.

Exclusive: Merck's consumer health sale at risk as Nestle bows out - sources

LONDON/FRANKFURT The sale of Merck KGaA's consumer health unit has been thrown off track after Nestle has pulled out, leaving the race to buy the maker of Seven Seas vitamins without its main contender, sources familiar with the matter told Reuters.

BRIEF-Forty Seven Says Agreement With Merck KGAA To Conduct Clinical Trials For Patients With Ovarian Cancer

* FORTY SEVEN - AGREEMENT WITH MERCK KGAA TO CONDUCT PHASE 1B CLINICAL TRIAL COMBINING HU5F9-G4 WITH AVELUMAB IN PATIENTS WITH OVARIAN CANCER Source text for Eikon: Further company coverage:

Nestle frontrunner for Merck KGaA's consumer health business - Bloomberg

ZURICH Nestle is the frontrunner to buy Merck KGaA's consumer health unit that could fetch as much as $5 billion, financial news service Bloomberg said on Wednesday, quoting unidentified sources familiar with the matter.

Nestle frontrunner for Merck KGaA's consumer health business: Bloomberg

ZURICH Nestle is the frontrunner to buy Merck KGaA's consumer health unit that could fetch as much as $5 billion, financial news service Bloomberg said on Wednesday, quoting unidentified sources familiar with the matter.

Nestle frontrunner for Merck KGaA's consumer health business - Bloomberg

ZURICH, Jan 10 Nestle is the frontrunner to buy Merck KGaA's consumer health unit that could fetch as much as $5 billion, financial news service Bloomberg said on Wednesday, quoting unidentified sources familiar with the matter.

Select another date: